Coronary Microvascular Disease: the Next Frontier in Ischemic Heart Disease

Marie Guerraty, MD, PhD, is currently an instructor in cardiovascular medicine ‪@pennmedicine‬.

Objectives:
1. Understand why Coronary Microvascular Disease (CMVD) is an important and prevalent clinical entity.
2. Draw from existing genomic and developmental research to gain insight into CMVD.
3. Understand how transcriptional coregulator Friend of GATA 2 (FOG2) may play a role in CMVD.

Follow Yale Cardiovascular Medicine on Twitter:   / yalecardiology  
Sign up for email updates: https://subscribe.yale.edu/

0:00 Introduction
2:24 Coronary Arterial Circulation
7:23 CAD GWAS = Ischemic Heart Disease GWAS
12:32 Phenome-Wide Association Study of non
15:26 Discrete left heart catheterization
16:44 Matched cohorts for deeper phenotypic
24:34 Using CRISPR/Cas9 genome
27:08 Angiogenic effects of
33:37 TWIST1 in Smooth Muscle Cells
38:00 TWIST1 Summary
46:40 Acknowledgements